<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154793">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02012491</url>
  </required_header>
  <id_info>
    <org_study_id>818434</org_study_id>
    <secondary_id>1R01HD071920-01A1</secondary_id>
    <nct_id>NCT02012491</nct_id>
  </id_info>
  <brief_title>Comparative Effectiveness of Pregnancy Failure Management Regimens</brief_title>
  <acronym>PreFaiR</acronym>
  <official_title>Comparative Effectiveness of Pregnancy Failure Management Regimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Courtney Schreiber</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the effectiveness of combination treatment
      (mifepristone premedication plus single-dose misoprostol) to single-dose misoprostol
      (standard of care) for the management of early pregnancy failure.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Gestational sac expulsion with one treatment dose and no need for additional medical or surgical intervention.</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Early Pregnancy Failure</condition>
  <arm_group>
    <arm_group_label>misoprostol plus mifepristone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>800 micrograms vaginal misoprostol, preceded by 200 milligrams oral mifepristone 24 hours prior</description>
  </arm_group>
  <arm_group>
    <arm_group_label>misoprostol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>800 micrograms of vaginal misoprostol alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <arm_group_label>misoprostol plus mifepristone</arm_group_label>
    <arm_group_label>misoprostol</arm_group_label>
    <other_name>Cytotec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifepristone</intervention_name>
    <arm_group_label>misoprostol plus mifepristone</arm_group_label>
    <other_name>Mifeprex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  between 5 and 12 completed weeks gestation

          -  18 years or older

          -  hemodynamically stable

          -  confirmed diagnosis of intrauterine embryonic/fetal demise or anembryonic gestation
             (ultrasound examination demonstrates a fetal pole without cardiac activity measuring
             between 5.3 and 40 mm or an anembryonic gestational sac between 21 and 45 mm, or
             growth less than 2 mm over a 5 day period or less than 3 mm over a 7 day period)

          -  willing and able to give informed consent

        Exclusion Criteria:

          -  diagnosis of incomplete or inevitable abortion (absent gestational sac and/or active
               bleeding, open cervical os)

          -  contraindication to mifepristone (chronic corticosteroid administration, adrenal
             disease)

          -  contraindication to misoprostol (glaucoma, mitral stenosis, sickle cell anemia, or
             known allergy to prostaglandin)

          -  cardiovascular disease (angina, valvular disease, arrhythmia, or cardiac failure)

          -  hemoglobin &lt;9.5 g/dL

          -  known clotting defect or receiving anticoagulants

          -  pregnancy with an IUD in place

          -  breastfeeding

          -  unwilling to comply with the study protocol and visit schedule

          -  any evidence of viable pregnancy

          -  possibility of ectopic pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Courtney A Schreiber, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mitchell Creinin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Davis Medican Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mitchell Creinin, MD</last_name>
      <email>mitchell.creinin@ucdmc.ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>Mitchell Creinin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Courtney Schreiber, MD</last_name>
      <email>schreibe@upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Courtney Schreiber, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 10, 2013</lastchanged_date>
  <firstreceived_date>December 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Courtney Schreiber</investigator_full_name>
    <investigator_title>Assistant Professor of Obstetrics and Gynecology</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mifepristone</mesh_term>
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
